Affordable Access

Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.

Authors
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Volume
14
Issue
11
Pages
1623–1628
Identifiers
PMID: 14581269
Source
Medline
License
Unknown

Abstract

Docetaxel and doxorubicin is an effective and well-tolerated combination in the neoadjuvant therapy of breast cancer. Future controlled trials are warranted to investigate the best schedules and to correlate response with biological factors.

Statistics

Seen <100 times